|2019 Novel Coronavirus (2019-nCoV)|
IDT has received inquiries from researchers from around the world who are interested in rapidly obtaining assays and developing vaccines targeting the Wuhan coronavirus (2019-nCoV). Supporting these efforts, the CDC and Chinese government have sequenced and submitted the coronavirus genome to the US NCBI GenBank® database . With our world-wide manufacturing capabilities, IDT is uniquely able to provide robust qPCR assays while avoiding contamination issues from synthesis of controls and related gene fragments.
In a swift response to the recent outbreak and rapid spread of 2019-nCoV, IDT is producing CDC assays designed by the US Centers for Disease Control and Prevention (CDC) for identification of virus. The assays are manufactured under ISO:13485 conditions and are available for research use only (RUO). In addition, the CDC has designed an RT-PCR assay and published a protocol for the detection of the 2019-nCoV [2,3]. We anticipate that the FDA will soon issue an Emergency Use Authorization to temporarily expand the use of assays to positively identify the coronavirus .
Advances in gene synthesis mean that subunit vaccines can be developed quickly from one or more antigen-presenting viral genes or peptide sequences, which circumvents the need for scientists to handle live and potentially dangerous pathogens, and eliminates the time needed to clone DNA fragments.
Use IDT double-stranded DNA fragments to create synthetic proteins designed as safe reagents for vaccine research. IDT offers 3 convenient options: linear gBlocks Gene Fragments, eBlocks Gene Fragments, or Custom Genes cloned into vectors. These are available in varying lengths and synthesis scales. Start your order, and we will help you choose the format that best fits your need.
CDC INFORMATION FOR LABORATORIES
Access the CDC’s latest laboratory guidance for 2019-nCoV RT-PCR assays.
|다음글||[IDT] PACE™ genotyping|